PMID- 30769136
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200415
IS  - 1878-7568 (Electronic)
IS  - 1742-7061 (Linking)
VI  - 88
DP  - 2019 Apr 1
TI  - Augmenting the synergies of chemotherapy and immunotherapy through drug delivery.
PG  - 1-14
LID - S1742-7061(19)30116-3 [pii]
LID - 10.1016/j.actbio.2019.02.012 [doi]
AB  - Despite the recent approvals of multiple cancer immunotherapies, low tumor 
      immunogenicity and immunosuppressive tumor microenvironments prevent a large 
      portion of patients from responding to these treatment modalities. Given the 
      immunomodulatory and adjuvant effects of conventional chemotherapy as well as its 
      widespread clinical use, the use of chemotherapy in combination with 
      immunotherapy (so-called chemoimmunotherapy) is an attractive approach to 
      potentiate the effects of immunotherapy in more patient populations. However, due 
      to the limited extent of tumor accumulation, poorly controlled interactions with 
      the immune system, and effects on systemic healthy tissues by chemotherapeutic 
      drugs, the incorporation of anti-cancer agents into biomaterial-based structures, 
      such as nanocarriers, is highly attractive to improve the safety and efficacy of 
      chemoimmunotherapy. Herein, we review the recent progress in drug delivery 
      systems (DDSs) for potentiating the immunomodulatory effects of chemotherapeutics 
      in chemoimmunotherapy, which represent among the most promising next generation 
      strategies for cancer treatment in the immunotherapy era. STATEMENT OF 
      SIGNIFICANCE: Given the benefits of cancer immunotherapy in inducing durable, 
      albeit low rates, of patient response, interest in the immunomodulatory and 
      adjuvant effects of conventional chemotherapy has been re-invigorated. This 
      review article discusses the recent progress towards understanding the synergies 
      between these two treatment types, how they can be used in combination (so-called 
      chemoimmunotherapy), and the potential for drug delivery systems to optimize 
      their effects in translational settings.
CI  - Copyright (c) 2019. Published by Elsevier Ltd.
FAU - Kim, Jihoon
AU  - Kim J
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, 315 Ferst Dr NW, Atlanta, GA 30332, United States; George W. Woodruff 
      School of Mechanical Engineering, Georgia Institute of Technology, 315 Ferst Dr 
      NW, Atlanta, GA 30332, United States.
FAU - Manspeaker, Margaret P
AU  - Manspeaker MP
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, 315 Ferst Dr NW, Atlanta, GA 30332, United States; School of Chemical 
      and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, 
      United States.
FAU - Thomas, Susan N
AU  - Thomas SN
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, 315 Ferst Dr NW, Atlanta, GA 30332, United States; George W. Woodruff 
      School of Mechanical Engineering, Georgia Institute of Technology, 315 Ferst Dr 
      NW, Atlanta, GA 30332, United States; Wallace H. Coulter Department of Biomedical 
      Engineering, Georgia Institute of Technology, 313 Ferst Dr NW, Atlanta, GA 30332, 
      United States; Emory University, 201 Dowman Drive, Atlanta, GA 30322, United 
      States; Emory University School of Medicine, 1365-C Clifton Road NE, Winship 
      Cancer Institute, Atlanta, GA 30322, United States. Electronic address: 
      susan.thomas@gatech.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190212
PL  - England
TA  - Acta Biomater
JT  - Acta biomaterialia
JID - 101233144
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - *Drug Delivery Systems
MH  - Humans
MH  - *Immunotherapy
MH  - Neoplasms/immunology/pathology/*therapy
MH  - Tumor Microenvironment/*immunology
OTO - NOTNLM
OT  - Cancer
OT  - Chemoimmunotherapy
OT  - Chemotherapy
OT  - Drug delivery systems
EDAT- 2019/02/16 06:00
MHDA- 2020/04/16 06:00
CRDT- 2019/02/16 06:00
PHST- 2018/11/15 00:00 [received]
PHST- 2019/01/25 00:00 [revised]
PHST- 2019/02/11 00:00 [accepted]
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PHST- 2019/02/16 06:00 [entrez]
AID - S1742-7061(19)30116-3 [pii]
AID - 10.1016/j.actbio.2019.02.012 [doi]
PST - ppublish
SO  - Acta Biomater. 2019 Apr 1;88:1-14. doi: 10.1016/j.actbio.2019.02.012. Epub 2019 
      Feb 12.